Archive - January 2018
Celgene to acquire Juno for $9b
Improving Performance And Regulatory Compliance With Instrument Calibration
Antibodies & Antibody Drug Conjugates
Celgene confirms rumours, with $9bn deal for Juno
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
Wickham Laboratories Holdings Announces Planning Application Approval
Biogen’s Spinraza to go before NICE
Abcam acquires rights to over 700 Roche products in new licensing deal